Abstract：【Objective】 To explore the expression and clinical significance of SOX2 and CARM1 in stage Ⅰ endometrial adenocarcinoma tissue.【Methods】 Pathological paraffin specimens of cancer tissue from patients with total hysterectomy for high and medium differentiated endometrioid adenocarcinoma, who admitted to the Department of Gynecology at the Affiliated Hospital of Inner Mongolia Medical University from January 2013 to December 2015, were enrolled in the observation group. While proliferative endometrial pathological paraffin specimens from patients who underwent total hysterectomy due to benign diseases such as uterine fibroids and adenomyosis were recruited in the control group. Immunohistochemical SP method was used to detect the expression levels of SOX2 protein and CARM1 protein in two groups and the results were compared between the two groups. 【Results】 The positive expression rates of both SOX2 protein and CARM1 protein in the observation group were significantly higher than those in the control group, with a statistically significant difference (P<0.05). The positive expression of SOX2 and CARM1 protein was related to histological differentiation in endometrioid adenocarcinoma (P<0.05). However, their expression was not related to patients' age, International Federation of Gynecology and Obstetrics (FIGO) and CA125 value (P> 0.05). There was a significant positive correlation between SOX2 and CARM1 protein expression in in endometrioid adenocarcinoma (P=0.010). 【Conclusion】 Highly expressed SOX2 protein and CARM1 protein may be involved in the pathogenesis of endometrioid adenocarcinoma. The two synergistically promote the occurrence and development of endometrioid adenocarcinoma. The higher expression level of SOX2 and CARM1 was found in moderately differentiated EAC compared to well differentiated ones, which may be novel factors that cause malignant behavior.
闫瑞娟, 张林燕. SOX2、CARM1在子宫内膜样腺癌 Ⅰ 期组织中的表达及其意义[J]. 医学临床研究, 2024, 41(1): 81-84.
YAN Ruijuan, ZHANG Linyan. The Expression and Clinical Significance of SOX2 and CARM1 in Stage Ⅰ Endometrioid Adenocarcinoma. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 81-84.
[1] 中国抗癌协会妇科肿瘤专业委员会. 子宫内膜癌诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6): 501-512. [2] THU K L, BECKER-SANTOS D D, RADULOVICH N, et al. SOX15 and other SOX family members are important mediators of tumorigenesis in multiple cancer types[J].Oncoscience,2014,1(5):326-335. [3] JAVAEED A, GHAURI S K. Metastatic potential and prognostic significance of SOX2: A meta-analysis[J].World J Clin Oncol,2019,10(6):234-246. [4] ZHAO G, WANG X Z, QU L M, et al.The clinical and molecular characteristics of sex-determining region y-box 2 and its prognostic value in breast cancer: a systematic meta-analysis[J].Breast Care (Basel),2021,16(1):16-26. [5] YUAN D D, WANG J, YAN M Y, et al. SOX2 as a prognostic marker and a potential molecular target in cervical cancer:A meta-analysis[J].Int J Biol Markers,2021,36(4):45-53. [6] 谢双双,张娟,尚丹丹,等.CDX2、SOX2在浆液性卵巢癌组织中的表达及其临床意义[J].中国计划生育学杂志,2021,29(11):2345-2349. [7] LIU K, MA J, AO J, et al. The Oncogenic Role and immune infiltration for CARM1 identified by pancancer analysis[J].J Oncol,2021,2021:2986444. [8] WEINA K, UTIKAL J. SOX2 and cancer: current research and its implications in the clinic[J].Clin Transl Med,2014,3:19. [9] ZHANG S Z, XIONG X F, SUN Y. Functional characterization of SOX2 as an anticancer target[J].Signal Transduct Target Ther,2020,5(1):135. [10] ZHOU X, ZHOU Y P, HUANG G R, et al. Expression of the stem cell marker, Nanog, in human endometrial adenocarcinoma[J].Int J Gynecol Pathol,2011,30(3):262-270. [11] PITYŃSKI K, BANAS T, PIETRUS M, et al. SOX-2, but not Oct4, is highly expressed in early-stage endometrial adenocarcinoma and is related to tumour grading[J].Int J Clin Exp Pathol,2015,8(7):8189-8198. [12] 程红霞,周庚寅.CARM1在乳腺癌中的表达及其对MDR1介导的多药耐药的调节[D].山东:山东大学,2013. [13] PENG B L, LI W J, DING J C, et al. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis[J].Theranostics,2020,10(8):3451-3473. [14] QIU Y Q, WANG H, LIAO P Y, et al. Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker[J].BMC Genom Data,2022,23(1):7.
2024, Vol. 41 
